Talking Precision Medicine

AI can propose a molecule or suggest the next experiment. But someone still has to run the experiment, check the result, and decide what to do with it. In this episode of Talking Precision Medicine, Rafael Rosengarten talks with Stacie Calad-Thomson , Global BD Lead for BioPharma Labs & Manufacturing at NVIDIA about connecting AI to the physical lab. They discuss why consistent experimental da...

Are we measuring progress in AI-driven drug discovery the right way? Rafael Rosengarten explores this question with Andrii Buvailo , co-founder of BioPharmaTrend and one of the industry’s most perceptive analysts of AI in biotech and pharma.  They trace the evolution of AI-driven drug discovery, examine why counting AI-discovered drugs gives an incomplete picture of progress, and explore where AI...

Artificial intelligence may be transforming drug discovery, but AI is only as powerful as the data it learns from. Behind many of today's scientific breakthroughs sits an invisible layer of expertly curated, harmonized knowledge that allows researchers to ask better questions and trust the answers. In this episode, Rafael speaks with Tim Walberg , President of CAS, about why scientific data cu...

Mental health remains one of medicine's greatest unmet needs. In this episode, Jacob Hooker explains how Sensorium Therapeutics is searching for new psychiatric medicines by combining traditional plant knowledge with cutting-edge drug development. Jacob joins Rafael Rosengarten to discuss how centuries of ethnobotanical knowledge, modern AI, and medicinal chemistry are helping uncover new trea...

In episode 58, Rafael sits down with James Zanewicz , CEO of Connect, to discuss the art and science of building innovation ecosystems. From Connect's origins as the world's first accelerator to the future of AI-powered healthcare, James shares lessons from a career spanning science, law, technology transfer, academic medicine, and ecosystem development. Together, they explore what makes S...

In this episode, Rafael Rosengarten sits down with Lisa Gurry , Chief Business Officer at GeneDx, to discuss the transformative role of genomic testing in rare disease diagnosis, therapeutic discovery, and precision medicine. Lisa shares GeneDx's mission to shorten the diagnostic odyssey for patients and families, explains how genomic data is accelerating drug development, and reflects on her...

In this episode, Rafael Rosengarten sits down with  Dr. Kamal Jethwani , VP of Digital Ventures at Moffitt Cancer Center, CEO of AccelerOnc Studio, and consulting CEO of Decimal Health. With over two decades in digital health, Kamal shares how Moffitt is transforming cutting-edge oncology expertise into scalable AI-native companies, why operational implementation matters more than most founders re...

Precision oncology promises more data, more insight, and better decisions, yet in practice it often brings more complexity. In a new episode Rafael Rosengarten is joined by Dr. Shakti Ramkissoon , VP of Oncology at Labcorp, to unpack the realities on the ground. From access gaps, reimbursement challenges and fragmented workflows to the promise of longitudinal data and AI-enabled clarity, Dr. Ramki...

In this episode, Rafael Rosengarten speaks with Dr. Sean Khozin , CEO of the CEO Roundtable on Cancer. Sean shares how pre-competitive collaboration across industry, academia, and regulators is helping address some of the biggest challenges in oncology. The conversation explores the role of data sharing initiatives like Project Data Sphere, the promise of AI in clinical trials and discovery, and S...

In this episode, I’m joined by Colette Delawalla , founder and CEO of Stand Up For Science. What began as frustration over a federal “banned words” list evolved into a national mobilization effort to defend scientific freedom and evidence-based policymaking. We talk about the organization’s origin story, its National Day of Action on March 7, 2026, the communication gap in science on the political...

In this episode, I’m joined by my longtime friend  Ian Simon , Head of Biotechnology at Aspis Intelligence. Ian’s path runs from grad school vaccine research at Yale to senior roles at the White House, HHS, NIH, the State Department, and the Office of Long Covid. We talk about de-risking young biotech companies, what Covid taught us about science and public health, and how new technologies like AI...

In this episode Rafael sits down with Michelle Chen , President and CEO of Form Bio, a techbio company using AI to advance genome engineering and the development of genetic medicines. Michelle shares her zigzag journey from scientist to executive, how her team is tackling the biggest bottlenecks in gene therapy, and why AI has become essential in designing safer, more effective treatments. ⁠⁠TPM E...

Today I’m joined by Mike Rossi , Vice President of Translational Science and Multi-modal Real-World Evidence Solutions at ConcertAI. Mike has built a career at the intersection of genomics, data science, and oncology, helping to bridge the gap between research and real-world clinical practice. We talk about what real-world data really means, how it becomes actionable evidence, and what it takes to...

Joining us on this episode is Mida Pezeshkian, an old colleague and friend. Mida’s career has spanned from the depths of stem cell science as a student to her current focus on product management in healthcare. We talk about what it really takes to launch products in this space, and how she helps customers bring truly transformational innovations to market. ⁠⁠TPM E49 highlights >⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Episo...

Today on the show, I’m joined by Michael Montalto , vice president of precision medicine at Amgen. Amgen is widely recognized as one of the most successful pharmaceutical companies in translating research and development into approved therapies. A key part of that success comes from their focus on precision medicine, and Mike brings a unique perspective from the forefront of that work. ⁠⁠TPM E48 h...

Joining us on this episode is  Tom Neyarapally , co-founder and CEO of Archetype Therapeutics, an exciting new AI-driven company in the drug discovery space. Archetype is an AI-native biotech pioneering the use of generative chemogenomics and patient clinicogenomic data to virtually screen billions of potential drug candidates each day. ⁠⁠TPM E47 highlights >⁠⁠⁠⁠⁠⁠⁠⁠ Episode 47 links: Archetype...

Stéphane Budel , founding partner at DeciBio, joins the Talking Precision Medicine Podcast to explore the future of the field. He unpacks how liquid biopsy, multi-omics, and AI are opening new doors for personalized care, why the diagnostics business model is holding innovation back, and what it will take to make complex tech usable for clinicians and patients alike. ⁠TPM E46 highlights >⁠⁠⁠⁠⁠⁠...

Today’s guests are Anna Berkenblit , Chief Scientific and Medical Officer at the Pancreatic Cancer Action Network, and Sudheer Doss , Chief Business Officer at PanCAN. The Pancreatic Cancer Action Network is the leading organization dedicated to advancing progress against pancreatic cancer. It empowers patients and caregivers, drives early detection strategies, and revolutionizes the development o...

Today’s guest is Najat Khan , Chief R&D Officer and Chief Commercial Officer at Recursion Pharmaceuticals. Recursion is widely recognized as one of the most visible—and so far, most successful—companies to emerge from the tech-bio movement. Many consider it the current industry leader. It has become an iconic name in the field of artificial intelligence for drug discovery. TPM E44 highlights &...

What a pleasure to welcome today’s guest, Ryan Fukushima , chief operating officer of TempusAI. Not only has Ryan helped build Tempus brick by brick from the earliest days, he is also CEO of Pathos AI, a biotech company using real world data and AI to develop true precision medicines. I don’t know how he juggles it all, but unless you’ve been hiding out these last few years, Tempus has become a ho...

Today my guest is  Joydeep Goswami , newly appointed President and CEO of the storied biotechnology company LGC. Joydeep is also a strategy advisor to Genialis. Join us as we discuss his remarkable career and lessons learned at each step of the way. Come on in and have a listen. Episode 42 links: ⁠⁠⁠⁠⁠⁠⁠TPM E42⁠⁠⁠ for highlights and links from this episode >⁠⁠⁠⁠⁠⁠ Tempus Announces a Collaborati...

This episode features a conversation with Shweta Maniar , who leads the Healthcare and Life Science effort at Google cloud. In just a few short years, artificial intelligence has gone from the stuff of hype and fairy tale to powerful and ubiquitous tools for all aspects of R&D and healthcare delivery. Google has been central to this sea change. I discuss with Shweta how her organization helps...

Our guest this episode is Charles Fisher , co-founder and currently Chief Scientific Officer of Unlearn. AI. Unlearn has been a leader in the advancement of Digital Twins as a tool to drastically improve the efficiency of clinical trials. Not only a visionary scientist and trailblazing entrepreneur, Charles is fearless with his hot takes. So sit back and enjoy this free wheeling conversation! Epis...

What a genuine pleasure to sit with Thierry Bernard , CEO of Qiagen. As I told Thierry, Qiagen is a truly iconic brand for anyone who came up through molecular biology laboratories in the past 30 years. Their products were ubiquitous, and crucial, to the success of our research. In this conversation, Thierry talks about his global vision for precision medicine, and his mantra that we leave no pati...

What a pleasure to sit down with my long time colleague and friend, Art Krieg, to discuss his latest venture, Zola Therapeutics, and his adventures in the great outdoors. Art has launched and exited a number of innovative biotechs, each time delving deeper into mechanisms by which we can harness the immune system for therapeutic purposes. Join us as we discuss how — despite a well earned retiremen...